Work

Updated Overall Survival (Os) from the Phase 3 Trial, Ca184-043: Ipilimumab (Ipi) Vs Placebo (Pbo) in Patients with Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu336.11

Authors: K. Fizazi, C.G. Drake, E.D. Kwon, A. Bossi, A.J. van den Eertwegh, H.I. Scher, T.M. Beer, M.B. McHenry, D. Liu, W.R. Gerritsen, C. Logothetis

Institutions: Université Paris-Sud, Institut Gustave Roussy, Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Mayo Clinic, Amsterdam UMC Location Vrije Universiteit Amsterdam, Memorial Sloan Kettering Cancer Center, OHSU Knight Cancer Institute, Bristol-Myers Squibb (United States), Radboud University Medical Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1932630807

FWCI: 1.861

Cites:

Cited by: 12

Related to: 10